Trial Profile
A Phase 2 proof of concept trial of TRV250 for acute migraine in patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2019
Price :
$35
*
At a glance
- Drugs TRV 250 (Primary)
- Indications Migraine
- Focus Proof of concept; Therapeutic Use
- Sponsors Trevena
- 04 Nov 2019 According to Trevena media release, the Company anticipates reporting topline data from this study in the second half of 2020
- 04 Nov 2019 Status changed from planning to recruiting according to Trevena media release
- 07 Aug 2019 According to a Trevena media release, the company plans to initiate this study in the fourth quarter of 2019